Allison DeAngelis from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: A reporter’s JPM notebook: a look ahead for biopharma VC investing - 5 days ago STAT+: Jiangsu Hengrui, a preferred China partner for U.S. biotech, hints at more deals - 5 days ago STAT+: Denali Therapeutics spinout raises $200M as neuro company resets - 14 days ago STAT+: With a major patent cliff coming, will JPM play host to some serious deal-making? - 14 days ago STAT+: Neumora’s antidepressant stumbles in first Phase 3 trial readout - 20 days ago STAT+: Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results - 23 days ago The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - about 1 month ago STAT+: Young biotech venture firm raises $500 million for its second fund - about 1 month ago STAT+: ‘Significant talent shortage’ threatens the rise of radiopharmaceuticals - about 2 months ago STAT+: Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger - about 2 months ago Pfizer’s new R&D head, a VC deep-dive, and a new FDA commissioner? - 2 months ago STAT+: Former NCI chief and serial biotech entrepreneur raise $70 million to start companies that fail fast - 2 months ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 3 months ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 3 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 3 months ago STAT+: Seaport Therapeutics adds another $225 million to coffers to embrace the ‘golden age of neuroscience’ - 3 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 3 months ago Biotech veteran Tony Coles on partisan politics and fulfilling a promise to his co-founder - 3 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 4 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 4 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 5 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 5 months ago STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance - 5 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 5 months ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 5 months ago STAT+: AI drug firm Recursion seeks to move from survival to industry domination - 5 months ago Listen: Drug pricing drops & psychedelics under fire - 5 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 6 months ago STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies - 6 months ago STAT+: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund - 6 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 6 months ago STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 8 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 8 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 9 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 10 months ago STAT+: Biotech startups post strongest financing numbers in two years - 10 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 10 months ago STAT+: Investors funnel $275 million into Paragon Therapeutics spinout - 10 months ago STAT+: As AI proliferates, biopharma companies seek to harness it in clinical trials - 10 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 10 months ago STAT+: How biotech investors spot opportunity when stocks are down — and up - 10 months ago Listen: Live! From the STAT Breakthrough Summit East - 10 months ago STAT+: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO - 10 months ago STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline - 10 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 10 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 11 months ago STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships - 11 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 11 months ago STAT+: Biotech launches with $82 million for Parkinson’s cell therapy - 11 months ago Q&A: A biotech VC leader shares her next big bets - 11 months ago
2	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Jiangsu Hengrui, a preferred China partner for U.S. biotech, hints at more deals - 5 days ago The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - about 1 month ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 3 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 3 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 3 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 4 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 4 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 5 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 5 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 5 months ago Listen: Drug pricing drops & psychedelics under fire - 5 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 6 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 6 months ago
3	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: With a major patent cliff coming, will JPM play host to some serious deal-making? - 14 days ago The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - about 1 month ago Pfizer’s new R&D head, a VC deep-dive, and a new FDA commissioner? - 2 months ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 3 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 3 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 3 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 4 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 4 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 5 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 5 months ago Listen: Drug pricing drops & psychedelics under fire - 5 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 6 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 6 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 8 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 9 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 10 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 10 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 10 months ago Listen: Live! From the STAT Breakthrough Summit East - 10 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 10 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 11 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 11 months ago
4	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Former NCI chief and serial biotech entrepreneur raise $70 million to start companies that fail fast - 2 months ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 3 months ago
5	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 3 months ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 5 months ago
6	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 3 months ago
7	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 3 months ago
8	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 10 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 10 months ago Listen: Live! From the STAT Breakthrough Summit East - 10 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 10 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 11 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 11 months ago
9	Mario Aguilar STAT News Reporter at STATnews. Previous engagements noted. Personal views. Brooklyn techhealth care	STAT+: How biotech investors spot opportunity when stocks are down — and up - 10 months ago